FDA Says COVID-19 Treatment Remdesivir Shouldn’t Be Compounded

Gilead Sciences’ FDA-approved antiviral treatment for COVID-19, Veklury (remdesivir), should not be compounded, the FDA has warned.

The agency said it has recently learned that “various entities” are offering to sell the active pharmaceutical ingredient in remdesivir to compounders and that the products could be “substandard or counterfeit.”

And even if they are not, compounders might find it hard to produce a final product that is sufficiently soluble and stable and has the right pH, the agency said.